Ranbaxy Laboratories will go for further acquisitions in the domestic and international sectors after emerging as a debt-free entity with the finalisation of the proposed deal with Japanese major Daiichi Sankyo, according to company CEO and MD Malvinder Mohan Singh.

Briefing the newsmen on the quarter two results of the company here on Tuesday, Singh said the deal was very much on the track and progressing. ``Once the deal is through, Ranbaxy will be debt-free and with the surplus cash in hand then, it will go for further acquisitions both in India and outside,'' he said.

The Japanese pharma major is taking over the stakes owned by the promoter family of Ranbaxy for 4.6 billion dollar. Singh said the shares will be transferred through the exchange or outside, depending on the regulatory approvals.

Referring to the controversy over the US probe into allegations of fabricating false data, he reiterated that some multinational company was trying to create troubles for Ranbaxy. But without revealing the name of the company, he said they had filed necessary details with the regulatory authorities in this regard and got details over the involvement of the rival company from the authorities.

"We hope that the motion in the US court would be withdrawn as we would be filing necessary data in this regard before the court by August 3,'' he said.

Ranbaxy chief expressed hope that the company would perform better in the next half year as the real results of its first-to-file privileges on certain products would start reflecting on the balance sheet from December this year.

With the settlement of some cases including that atorvastatin with Pfizer, the company is expecting over 16 billion dollar innovative sales during the period of 2008-14. Lipitor will be launched in USA on November 30, looking to grab a considerable chunk from the world's most-prescribed cholesterol-lowering drug market, he added.